Co-existence of EGFR T790M-acquired lung adenocarcinoma and transformation into small-cell carcinoma in different organs after osimertinib treatment. A case report

We report a rare case of a 59-year-old man with EGFR-mutated lung adenocarcinoma who developed osimertinib resistance, with coexisting T790M-positive adenocarcinoma and T790M-negative small-cell carcinoma in different organs. After treatment with gefitinib, chemotherapy, osimertinib, and subsequent chemotherapy, the patient presented with progressive disease, including pericardial effusion and mediastinal lymphadenopathy. Cytology of the pericardial fluid confirmed adenocarcinoma, while lymph node biopsy revealed transformation to small-cell carcinoma. Rechallenge with osimertinib successfully controlled the pericardial effusion, but the disease ultimately progressed. This case emphasizes the importance of re-biopsy for understanding resistance mechanisms and highlights the challenges of managing dual histologic transformation in lung cancer, particularly when transformation to small-cell carcinoma occurs in different anatomical sites.